Non-Profit Trusted Source of Non-Commercial Health Information
The Original Voice of the American Academy of Anti-Aging, Preventative, and Regenerative Medicine
logo logo
Women's Health

FDA accepts Nastech plan for osteoporosis nasal spray

15 years, 9 months ago

2102  0
Posted on Feb 20, 2004, 7 a.m. By Bill Freeman

Herald Writer BOTHELL -- Nastech Pharmaceutical Co. said this week that the U.S. Food and Drug Administration has accepted its new drug application for a nasal spray to treat osteoporosis. While the FDA reviews the application, the Bothell company said it is working on marketing and distribution agreements for the drug.

Herald Writer BOTHELL -- Nastech Pharmaceutical Co. said this week that the U.S. Food and Drug Administration has accepted its new drug application for a nasal spray to treat osteoporosis. While the FDA reviews the application, the Bothell company said it is working on marketing and distribution agreements for the drug. Nastech's new spray would be a generic drug similar to Miacalcin nasal spray, which is made by Swiss-based Novartis AG. Last year, Miacalcin sales reached $239 million in the United States and $389 million worldwide. "It's a growing market," said Matthew Haines, spokesman for Nastech.

Source: http://www.heraldnet.com/Stories/04/2/19/18205403.cfm



[Editor: The preceding article was not written by A4M/WHN]

WorldHealth Videos

WorldHealth Sponsors